Recent TBPH Stock Price | TBPH Stock Predictions | |
$9.22 | +78.96% |
$16.50 |
Recent TBPH Analyst Ratings Breakdown, Making TBPH Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 3 | 2 | 2 | 2 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 2 | 2 | 2 | 2 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 1.8 | 2.0 | 2.0 | 2.0 |
For the TBPH stock predictions from the analysts covering Theravance Biopharma, Inc., we have collected all of the individual TBPH stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 4 different analysts covering TBPH (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since TBPH stock predictions may vary widely, another useful metric to consider is the median TBPH stock prediction, which represents the price at which half of the analysts
made TBPH stock predictions that were higher and half made TBPH stock predictions that were lower. This makes for a different take on the TBPH stock predictions out there, as compared to average or mean.
And that median across all the individual TBPH stock predictions was: $17.5 as of 2024-04-24.
The very highest of the TBPH stock predictions for one year price target was $21.0, while the very lowest of the TBPH stock predictions in the analyst group was
$10.0 (with a standard deviation of $5.066). Get the latest Zacks research report on TBPH — FREE
Find out: TBPH next earnings date »
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
CINF Stock Predictions
NJR Stock Predictions
ENVA Stock Predictions
CAH Stock Predictions
TRVI Stock Predictions
AAL Stock Predictions
III Stock Predictions
USNA Stock Predictions
COE Stock Predictions
|
|
Buy (3.20 out of 4) 44th percentile
(ranked lower than approx. 56% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |